Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Inozyme Pharma Inc (NQ: INZY ) 5.245 +0.065 (+1.25%) Streaming Delayed Price Updated: 12:04 PM EDT, Oct 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Inozyme Pharma Inc < Previous 1 2 3 4 Next > Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look' September 12, 2024 Stifel initiates coverage on Inozyme Pharma with a Buy rating and a $16 price target, highlighting INZ-701's potential to treat rare diseases like ENPP1 and ABCC6 deficiencies. Via Benzinga This AutoNation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday September 12, 2024 Via Benzinga Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session August 19, 2024 Via Benzinga ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday August 19, 2024 Via Benzinga Inozyme Pharma: Q4 Earnings Insights March 12, 2024 Via Benzinga 6 Analysts Have This to Say About Inozyme Pharma September 27, 2023 Via Benzinga INZY Stock Earnings: Inozyme Pharma Misses EPS for Q2 2024 August 06, 2024 INZY stock results show that Inozyme Pharma missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace INZY Stock Earnings: Inozyme Pharma Misses EPS for Q1 2024 May 07, 2024 INZY stock results show that Inozyme Pharma missed analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace 12 Health Care Stocks Moving In Monday's After-Market Session April 29, 2024 Via Benzinga Top 5 Health Care Stocks That May Plunge In March March 28, 2024 As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. Via Benzinga Inozyme Pharma Posts Encouraging Data From Rare Calcification Disorders September 26, 2023 Inozyme Pharma Inc (NASDAQ: INZY) announced interim safety, pharmacokinetic (PK), pharmacodynamic (PD), and exploratory efficacy data from its ongoing Phase 1/2 trials of INZ-701 in adults with Via Benzinga Analyst Expectations for Inozyme Pharma's Future September 08, 2023 Via Benzinga 4 Analysts Have This to Say About Inozyme Pharma August 09, 2023 Via Benzinga Analyst Ratings for Inozyme Pharma April 19, 2023 Via Benzinga 4 Analysts Have This to Say About Inozyme Pharma March 23, 2023 Via Benzinga Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session April 09, 2024 Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free Via Benzinga 12 Health Care Stocks Moving In Monday's After-Market Session September 25, 2023 Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session July 27, 2023 Via Benzinga Inozyme Outlines Plans For Pediatric Trial For ENPP1 Deficiency Treatment: Targets 2026 Commercial Launch For INZ-701 July 26, 2023 Following meetings with the FDA and the European Medicines Agency's Paediatric Committee, Inozyme Pharma Inc (NASDAQ: INZY) updated its global development strategy for INZ-701, a Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session July 26, 2023 Via Benzinga Recap: Inozyme Pharma Q1 Earnings May 09, 2023 Inozyme Pharma (NASDAQ:INZY) reported its Q1 earnings results on Tuesday, May 9, 2023 at 08:30 AM. Here's what investors need to know about the announcement. Earnings Inozyme Pharma beat estimated... Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session April 06, 2023 Via Benzinga Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session March 31, 2023 Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter. Via Benzinga Around $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying March 31, 2023 The Dow Jones closed higher by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or ... Via Benzinga Why Safe & Green Holdings Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket March 30, 2023 Gainers Boxed, Inc. (NYSE: BOXD) gained 43.3% to $0.2303 in pre-market trading after declining 6% on Wednesday. Boxed recently said it is evaluating potentially filing for relief under the U.S.... Via Benzinga $1.6M Bet On ATAI Life Sciences? Check Out These 4 Penny Stocks Insiders Are Buying March 30, 2023 The Dow Jones closed higher by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2023 March 23, 2023 Via Benzinga 89bio To Rally 265%? Here Are 10 Other Analyst Forecasts For Thursday March 23, 2023 Baird cut the price target for Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) from $14 to $11. Baird analyst Justin Kleber maintained an Outperform rating. Petco Health and Wellness shares rose... Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session February 20, 2023 Via Benzinga Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday's Mid-Day Session February 17, 2023 Gainers Ibio Inc (NYSE: IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology target program. Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.